Loading
Life sciences · Journal article
Cancer Drug Resistance · October 19, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Pancreatic ductal adenocarcinoma (PDAC) remains one of the most treatment-refractory malignancies, with limited and often transient benefit from chemotherapy, targeted therapy, immunotherapy, and radiotherapy. Therapeutic resistance is increasingly recognized as an ecosystem-level process arising from reciprocal interactions between malignant cells and the tumor microenvironment (TME). Dense extracellular matrix, cancer-associated fibroblasts (CAFs), pancreatic stellate cells (PSCs), dysfunctional vasculature, immunosuppressive myeloid and lymphoid populations, hypoxic niches, metabolic networks, microbiota, extracellular vesicles (EVs), and neural components collectively restrict drug delivery and promote adaptive survival, immune escape, stemness, and treatment-induced evolution. This review integrates these processes into a PDAC resistance ecosystem framework. We discuss how stromal remodeling, hypoxia-driven adaptation, metabolic-immune crosstalk, extracellular communication, cancer stem cell plasticity, and TME-regulated autophagy and ferroptosis contribute to resistance across therapeutic modalities. We further evaluate emerging strategies involving stromal reprogramming, myeloid and immune remodeling, metabolic intervention, hypoxia targeting, and regulated cell-death sensitization. Particular emphasis is placed on the limited clinical translation of indiscriminate stromal depletion and single-target approaches. Finally, we propose that spatial multi-omics, longitudinal biomarker profiling, and adaptive combination therapy will be required to identify dominant resistance programs and guide patient-specific intervention in PDAC.